Display options
Cite
Yan Q, Luo H, Wang B, et al. Correlation between PKB/Akt, GSK-3β expression and tubular epithelial-mesenchymal transition in renal allografts with chronic active antibody-mediated rejection. Exp Ther Med. 2017;13(5):2217-2224doi: 10.3892/etm.2017.4261.
Yan, Q., Luo, H., Wang, B., Sui, W., Zou, G., Chen, H., & Zou, H. (2017). Correlation between PKB/Akt, GSK-3β expression and tubular epithelial-mesenchymal transition in renal allografts with chronic active antibody-mediated rejection. Experimental and therapeutic medicine, 13(5), 2217-2224. https://doi.org/10.3892/etm.2017.4261
Yan, Qiang, et al. "Correlation between PKB/Akt, GSK-3β expression and tubular epithelial-mesenchymal transition in renal allografts with chronic active antibody-mediated rejection." Experimental and therapeutic medicine vol. 13,5 (2017): 2217-2224. doi: https://doi.org/10.3892/etm.2017.4261
Yan Q, Luo H, Wang B, Sui W, Zou G, Chen H, Zou H. Correlation between PKB/Akt, GSK-3β expression and tubular epithelial-mesenchymal transition in renal allografts with chronic active antibody-mediated rejection. Exp Ther Med. 2017 May;13(5):2217-2224. doi: 10.3892/etm.2017.4261. Epub 2017 Mar 24. PMID: 28565830; PMCID: PMC5443285.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 May;13(5):2217-2224. doi: 10.3892/etm.2017.4261. Epub 2017 Mar 24.

Correlation between PKB/Akt, GSK-3β expression and tubular epithelial-mesenchymal transition in renal allografts with chronic active antibody-mediated rejection.

Experimental and therapeutic medicine

Qiang Yan, Hao Luo, Baoyao Wang, Weiguo Sui, Guimian Zou, Huaizhou Chen, Hequn Zou

Affiliations

  1. Department of Nephrology, Guilin 181st Hospital, Guangxi Key Laboratory of Metabolic Diseases Research, Guilin, Guangxi 541002, P.R. China.
  2. Department of Oncology, No. 454 Hospital of the PLA, Nanjing, Jiangsu 210002, P.R. China.
  3. Department of Nephrology, Institute of Nephrology and Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, P.R. China.

PMID: 28565830 PMCID: PMC5443285 DOI: 10.3892/etm.2017.4261

Abstract

Chronic antibody-mediated rejection (ABMR) is a major cause of the transplant renal interstitial fibrosis and transplanted kidney epithelial cell transdifferentiation is one of the main mechanisms. The transforming growth factor (TGF)-β1/integrin-linked kinase (ILK) signaling pathway has a significant role in the epithelial-mesenchymal transition (EMT) of renal tubular epithelial cells; however, the molecular mechanisms of this process have remained elusive. The present study confirmed that Akt and glycogen synthase kinase (GSK)-3β, as TGF-β1 downstream signaling factors, are involved in fibrotic processes caused by kidney disease, which, however, has been rarely reported in the kidney transplant field. Based on the Banff 2009 standard, transplanted kidney specimens were classified according to the fibrosis level. The results showed that with the reduction of the interstitial fibrosis level, E-cadherin expression was gradually reduced, while α-smooth muscle actin expression progressively increased. The expression of Akt and GSK-3β in normal human kidney tissue was not obvious but showed a marked increase with the aggravation of the interstitial fibrosis level, which confirmed the occurrence of EMT during the fibrosis process, and that phosphorylated (p)-Akt and GSK-3β have an important role in the EMT process in the transplanted kidney. A correlation analysis of p-Akt, GSK-3β, TGF-β1 and ILK suggested that overexpression of p-Akt and GSK-3β may induce and mediate the transdifferentiation of renal tubular epithelial cells to myofibroblasts and that this proceeds via TGFβ1/ILK signaling pathways.

Keywords: E-cadherin; chronic active antibody-mediated rejection; epithelial-mesenchymal transition; glycogen synthase kinase 3β; interstitial fibrosis and tubular atrophy; protein kinase B; transforming growth factor beta1; transplantation

References

  1. J Am Soc Nephrol. 2008 Feb;19(2):380-7 - PubMed
  2. Am J Transplant. 2010 Mar;10(3):464-71 - PubMed
  3. Am J Transplant. 2006 May;6(5 Pt 1):867-75 - PubMed
  4. Oncogene. 2005 Nov 14;24(50):7443-54 - PubMed
  5. Am J Physiol Renal Physiol. 2010 May;298(5):F1263-75 - PubMed
  6. Biochem Biophys Res Commun. 2004 Apr 16;316(4):997-1001 - PubMed
  7. Am J Physiol Renal Physiol. 2005 Apr;288(4):F703-13 - PubMed
  8. Am J Transplant. 2008 Sep;8(9):1852-63 - PubMed
  9. Am J Physiol Renal Physiol. 2008 Jul;295(1):F215-25 - PubMed
  10. J Clin Invest. 2003 Aug;112(4):503-16 - PubMed
  11. Transplant Proc. 2008 Dec;40(10 Suppl):S2-4 - PubMed
  12. Cell Biochem Biophys. 2011 Sep;61(1):73-81 - PubMed
  13. Mol Cell Biol. 1999 Nov;19(11):7420-7 - PubMed
  14. J Am Soc Nephrol. 2004 Feb;15(2):390-7 - PubMed
  15. J Biol Chem. 2004 Jan 23;279(4):2632-9 - PubMed
  16. Am J Transplant. 2010 Apr;10(4):952; author reply 953 - PubMed
  17. Cancer Metastasis Rev. 2003 Dec;22(4):375-84 - PubMed
  18. Cell Biol Int. 2002;26(5):463-76 - PubMed
  19. Oncogene. 2000 Nov 16;19(48):5444-52 - PubMed
  20. Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11211-6 - PubMed
  21. Mol Med. 2008 May-Jun;14(5-6):276-85 - PubMed
  22. J Am Soc Nephrol. 2004 Jan;15(1):1-12 - PubMed
  23. J Biol Chem. 2003 Apr 4;278(14):12537-45 - PubMed
  24. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4374-9 - PubMed
  25. J Biol Chem. 2008 Mar 21;283(12 ):7401-10 - PubMed
  26. Transpl Immunol. 2010 May;23(1-2):1-5 - PubMed
  27. Diagn Pathol. 2012 Jan 13;7:5 - PubMed
  28. J Cell Biochem. 2011 Jun;112(6):1585-92 - PubMed
  29. Curr Opin Nephrol Hypertens. 2003 Jan;12(1):25-9 - PubMed
  30. Neuroreport. 2003 Dec 19;14 (18):2415-9 - PubMed
  31. J Am Soc Nephrol. 2005 Jul;16(7):1966-76 - PubMed

Publication Types